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Abstract
Objective: The study aim is to verify whether treatment with a new combi-
nation of tanacethum partenium, 5-hydrossitriptophan (5-http) and magne-
sium (Aurastop®) reduces headache frequency and intensity in patients suffer-
ing from episodic migraine without aura when used in migraine prevention.
Methods: Forty patients, suffering from migraine without aura for at least 6 
months with monthly frequency of 3 to 8 crises and presence of headache of 4 
to12 days, were enrolled in this open study and treated orally with Aurastop twice 
daily for 3 months. The primary endpoint was reduction of migraine frequency 
(headache days per month) over an observation period of 3 months. The second-
ary endpoint was a composite of monthly frequency and intensity of pain crises, 
analgesics use (number of medications) and subjective change of pain intensity. 
Results: All the parameters significantly improved at the end of treatment with Au-
rastop. We observed a significant reduction of the number of headache days (from 
8.8 ± 2.0 before treatment to 2.7 ± 1.7 post treatment, p < 0.001), as well as of the 
number of attacks (from 5.0 ± 1.2 per month to 2.1 ± 0.9 per month, p < 0.001), 
of pain intensity (from Visual Analogic Scale [VAS] 6.9 ± 1.0 to 3.3 ± 1.5, p < 
0.001), and of the number of analgesics assumed by each subject (from 8.5 ± 1.6 per 
month to 2.4 ± 1.5 per month, p < 0.001). No serious adverse events were observed.
Conclusion: Though obtained in the setting of an open-trial, our findings suggest that 
the new combination of tanacethum partenium, 5-hydrossitriptophan (5-http) and 
magnesium (AURASTOP®) is a promising approach for migraine prevention and 
warrant further investigation to confirm the safety and efficacy of this treatment. 
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Introduction
 A number of epidemiologic studies have consistent-
ly indicated that the prevalence of migraine is about 15 - 18% 
among women and 6 % among men in Western Countries, 
with a pick between 22 ad 55 years[1]. Migraine is a chronic, 
disabling disease, with high impact in terms of social and eco-
nomic costs[2]. Based on these characteristics, the WHO has re-
cently included migraine among the 20 most disabling diseases 
affecting women between 15 and 45 years of age[3]. In particular, 
chronic headache has become the leading cause of disability and 
abuse of medical resources, accounting for up to 80% of the 
whole economic budget for public healthcare. In Italy, the direct 
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and indirect costs of migraine have been estimated to be about 
6 billion euros per year. The identification of migraine sufferers 
as well as the most appropriate management of these cases rep-
resents, therefore, a field of need. In this regard, it is generally 
accepted that a prophylactic treatment for migraine should be 
started for patients suffering disabling migraine for at least 4 
days per month, or when pain crises do not respond to symptom-
atic medications.     
 The main goal of migraine prophylaxis is to reduce the 
frequency of attacks and patient disability, as well as to improve 
quality of life. A prophylactic therapy is considered effective 
when it reduces of at least 50% the frequency of migraine at-
tacks.  
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 Agents that have been considered for migraine prophy-
laxis according to several national and international guidelines 
include, among the others, beta-blockers, calcium antagonists, 
serotonin reuptake inhibitors, anti-depressants, anti-epileptics, 
phytotherapics[4], and magnesium.
 Although the mechanisms of action of these molecules 
in migraine prevention are poorly known, their effects on the 
vessel wall, on neurons, as well as on specific neurotransmitters 
involved in migraine biology have been hypothesized based on 
numerous pre-clinical observations. 
 The biological origin of migraine, in fact, is likely 
multifactorial. Clinical studies suggest abnormal cortical, cere-
brovascular, and immune functions. However, it is now well-ac-
cepted that the pain, persistence and throbbing features of mi-
graine are mediated by increased sensitivity (i.e. sensitization) 
and the ensuing activation of sensory neurons innervating in-
tracranial meninges and their related large blood vessels. These 
are the first-order neurons in the migraine pain pathway. Given 
the increasing importance placed on central and peripheral sen-
sitization in the pathogenesis of migraine, the mechanisms of 
activation of trigeminal sensory afferents take on a central role. 
Sensitization results from the local release of neuropeptides that 
cause vasodilatation (mediated by calcitonin gene-related pep-
tide) and an increase in vascular permeability (mediated by sub-
stance P and neurokinin A) accompanied by mast cell activation. 
Mast cells, members of the innate immune system, participate in 
numerous physiological and pathophysiological conditions.
 The emergence of a local inflammatory response in the 
meninges is widely viewed as a potential contributor to the ac-
tivation and sensitization of meningeal nociceptors during mi-
graine. Activation of resident immune cells such as mast cells, 
which are a prominent feature of the intracranial meninges, is 
likely to serve as a critical step in promoting enhanced excitabil-
ity of meningeal nociceptors. 
 Activation and sensitization of primary afferent men-
ingeal nociceptive neurons, the peripheral arm of the trigemi-
nal-vascular system, appears to constitute one of the earliest 
events promoting the intracranial pain of migraine. These ob-
servations thus posit that meningeal mast cells, by virtue of their 
proximity both to meningeal blood vessels and nociceptive ax-
ons, may release a host of pro-inflammatory/algesic mediators 
responsible for the vasodilatatory phase of migraine associated 
with throbbing pain. These data suggest that controlling menin-
geal nociceptor excitability might be achieved by acting on mast 
cell activation. 
 A proposed mechanism of action involves partheno-
lide specifically binding to and inhibiting IκB kinase complex 
IKKβ. IKKβ plays an important role in proinflammatory cyto-
kine-mediated signaling. Parthenolide may also interact with 
TRPA1 nucleophilic sites, suggesting that feverfew antimigraine 
effect derives from its ability to target TRPA1. TRPA1 partial 
agonism, together with desensitization and nociceptor defunc-
tionalization, ultimately resulting in inhibition of CGRP release 
within the trigeminovascular system, may contribute to the an-
timigraine effect of parthenolide[5-7].
 Glutamate is another neuropeptide likely involved in 
migraine pathogenesis. Actually, as it exerts an excitatory effect 
on first and second order neurons and it is involved in the acti-
vation of the trigeminovascular system, it is implicated in both 
migraine attack and the activity of the “migraine generator” in 
the brainstem. This makes it a key player in the activation and 
propagation of cortical spreading depression. 
 N-methyl-D-Aspartate (NMDA) is the post-synap-
tic glutamatergic receptor involved in central sensitization and 
cortical spreading depression, as demonstrated by its activation 
during migraine attacks[8]. NMDA receptors are activated by in-
creased synaptic levels of glutamate, while they are inhibited by 
magnesium[9-11].  
 Glutamate levels are regulated by kynurenine[12] which 
metabolizes l-triptophan in kynurenic acid (KYNA) and quin-
olinic acid (QUINA). The NMDA receptor antagonist KYNA, 
in particular, inhibits glutamatergic pathway by blocking gluta-
mate release and neurotransmission through its action on glycin 
Glu N1 binding site. It has been recently observed that in mi-
graineurs the kynuretic pathway is shifted towards the conver-
sion of KYNA in Antralinic Acid (ANA), as supported by the 
elevated plasma levels of ANA and the reduced concentration of 
KYNA and QUINA in these patients, with the consequent loss of 
inhibitory control on glutamate and its excitatory effects. 
 ANA has also a direct neurotoxic effect through the 
release of free radicals. Low plasma levels of KYNA may be 
considered a reliable marker of NMDA receptor activation.  
Cerebral levels of KYNA can be increased by the assumption of 
its precursor 5-HTP[13].
 Based on the mechanisms described above, the com-
bination of 3 components, tanacetum parthenium, 5-HTP, and 
magnesium is expected to synergistically influence the biologic 
pathways involved in migraine pathogenesis, and, therefore, to 
have a therapeutic potential in migraine prevention. 
Patients and Methods
 Patients with episodic migraine as defined by the In-
ternational Headache Society[14] were consecutively recruited 
among those referring to the Headache Center of the Istituto 
Clinico Citta’ di Brescia. Criteria for patients selection were: 1) 
age between 18 and 65 years; 2) diagnosis of migraine with-
out aura, according to the International Headache Society; 3) 
migraine for at least 6 months with a monthly crisis frequency 
ranging from 3 to 8, 4) headache duration ranging from 4 to 
12 days per month, and 5) no other migraine preventive thera-
pies. Patients with psychiatric co-morbidity, suffering from oth-
er types of acute or chronic pain, or with concomitant kidney 
failure, neurological or oncological diseases or pregnancy were 
considered non-eligible for the study. 
 The primary endpoint of the study was modification of 
migraine frequency (headache days per month) over an observa-
tion period of 3 months. The secondary endpoint was a compos-
ite of monthly frequency and intensity of pain crises, analgesics 
use (number of medications) and subjective change of pain in-
tensity.
 Patients who qualified for the study did not receive any 
prophylactic treatment for the first month since their enrollment 
in the study, then they received an association of Tanacetum 
Parthenium 150 mg (1, 2 mg of Partenolide), 5-HTP 20 mg, 
Magnesium 185 mg (Dietary supplement Aurastop®, Aesculapi-
us Farmaceutici) twice daily for 3 months. 
 At baseline evaluation all patients underwent a thor-
ough neurological examination and were carefully instructed on 
how to keep record of migraine attacks in their headache diary on 
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a day-to-day basis. In particular, they were instructed to register: 
1) attacks frequency, pain intensity (using the VAS scale, rang-
ing from 1 to 10) and duration; 2) response to analgesics based 
on a self-rate scale ranging between 1 (minimum response) and 
5 (maximum response) over the time period (1 month) with no 
preventive therapy and that (3 months) taking Aurastop. Safety 
was evaluated by treatment discontinuation rate and the occur-
rence of serious and otherwise adverse events. 
Statistical Analysis
 Categorical variables are reported as counts and per-
centages. Dependent variables were compared by McNemar’s 
χ2 analysis. Wilcoxon’s signed rank test was used to compare 
migraine characteristics before and after treatment. Statistical 
analyses were performed using SPSS 21.0 (IBM SPSS Statistics 
2013, Armonk, NY, USA). 
Results
 Overall, 40 patients (15 males/and 25 females; mean 
age, 35, 6 years, range, 19 - 54) were enrolled in the study. One 
out of the 40 patients withdrew after 1 month of treatment be-
cause of non-improvement and one was lost to follow-up.
 The results of the analysis are summarized in Table 1. 
We observed a significant reduction of the number of headache 
days (from 8.8 ± 2.0 before treatment to 2.7 ± 1.7 post treatment, 
p < 0.001), as well as of the number of attacks (from 5.0 ± 1.2 
per month to 2.1 ± 0.9 per month, p < 0.001), of pain intensity 
(from VAS 6.9 ± 1.0 to 3.3 ± 1.5, p < 0.001), and of the number 
of analgesics assumed by each subject (from 8.5 ± 1.6 per month 
to 2.4 ± 1.5 per month, p < 0.001; Figure 1). None of the patients 
reported any treatment-related adverse events.
Table 1: Migraine characteristics before and after prophylactic treat-
ment with Aurastop.
Migraine characteristics Baseline Post-
treatment
p-value
Pain intensity (0 to 10) 6.9 ± 1.0 3.3 ± 1.5 < 0.001
Number if attacks/month 5.0 ± 1.2 2.1 ± 0.9 < 0.001
Number of days/month 8.8 ± 2.0 2.7 ± 1.7 < 0.001
Number of analgesics 8.5 ± 1.6 2.4 ± 1.5 < 0.001
Analgesics (yes/no) 41(100.0) 35(89.7) 0.125
Figure 1: Comparison of individual migraine characteristics according 
to treatment-phase. 
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 Another notable finding derived from the analysis of 
the headache diaries, was that the results at the 3-month time 
point reported above were already detectable after one month of 
prophylactic therapy with Aurastop.
Discussion 
 The results of the present study highlight the efficacy 
and the safe profile of the combination of Tanacetum Parthe-
nium, 5-HTP and magnesium in migraine prophylaxis. Both, 
the frequency and the duration of migraine attacks as well as 
the intensity of pain improved significantly in most of the pa-
tients treated. These findings, in addition to the more favorable 
response to analgesics and the need of a reduced number of these 
medications in patients receiving Aurastop lead to the specula-
tion that the 3 molecules in combination might act synergistically 
on different pathways involved in migraine biology: neurogen-
ic inflammation, neural transmission, and central sensitization. 
The well-known phenomenon of Cortical Spreading Depression 
(CSD), involved in the pathogenesis of both migraine with-
out aura and migraine with aura, has been consistently related 
to the status of inter-critical cortical brain hyperexcitability of 
migraineurs. This emphasizes the physiologic role of magne-
sium in the regulation of such a neuronal excitability. Among 
the many actions, intracellular magnesium acts as a physiologic 
calcium-antagonist, thus reducing the toxic effects of calcium, 
whereas suboptimal concentrations of magnesium favor free 
radical accumulation within the cell, which, in turn, may trig-
ger a migraine attack. Furthermore, magnesium inhibits NMDA 
receptors, which are involved in the glutamate-dependent ex-
citatory pathways at the basis of the neurogenic inflammation. 
Moreover, brain concentration of kynurenic acid (Kyna), a tryp-
tophan derivative which further acts as an endogenous NMDA 
receptor antagonist, increases with increasing serum levels of its 
precursor 5HTP. Giving 5HTP as a drug may, therefore, increase 
Kyna levels and influence Kyna pathways, leading to the inhibi-
tion of peripheral NMDA receptors and the consequent activa-
tion of the trigeminovascular system, as well as of CSD. 
 Finally, TRPA1 and NMDA receptors with glutamate 
and calcitonin-gene-related peptide (CGRP) play a key role in 
neurogenic inflammation, which leads to the sensitization of 
trigeminal nucleus caudalis in the lower brainstem and upper 
cervical cord and, consequently, of all structures involved in the 
central transmission of nociceptive information.  
 Molecules proved to be migraine generators act as TRP 
receptors activators. These, in turn, generate neurogenic inflam-
mation leading to painful attacks through the release of CGRP 
from perivascular nerve terminals. Such a cascade might be in-
terrupted by partenolide, a TRP receptors inhibitor. Partenolide 
is, moreover, a powerful inhibitor of nitric oxide synthase and, 
consequently, of nitric oxide (NO) production. All the findings 
observed in the present study can, therefore, be interpreted as 
clinical manifestation of the interference with the phenomenon 
of central sensitization, as well as with the central transmission 
of nociceptive information at synaptic level, TRPA1 channels, 
and NMDA receptors determined by Aurastop.  
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Conclusion
 In spite of the methodological limitations inherent in 
the present pilot, observational study lacking a control group, 
our findings emphasize the potential influence of the combina-
tion of different molecules on the complex biologic mechanisms 
causing migraine. In particular, tanacetum parthenium + 5-HTP 
+ Magnesium appear as a promising association of molecules 
for migraine prophylaxis with an excellent safety profile. Fur-
ther clinical trials are warranted in order to investigate the poten-
tials of this compound in preventing migraine, either given alone 
or in combination with other molecules.
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